Journal
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Volume 15, Issue 5, Pages 291-303Publisher
WILEY
DOI: 10.1002/pds.1200
Keywords
confounding; bias; sensitivity analysis; claims databases; epidemiologic methods; pharmacoepidemiology
Funding
- AHRQ HHS [R01-HS010881] Funding Source: Medline
- NIA NIH HHS [R01-AG023178, R01-AG21950] Funding Source: Medline
Ask authors/readers for more resources
Background Large health care utilization databases are frequently used to analyze unintended effects of prescription drugs and biologics. Confounders that require detailed information on clinical parameters, lifestyle, or over-the-counter medications are often not measured in such datasets, causing residual confounding bias. Objective This paper provides a systematic approach to sensitivity analyses to investigate the impact of residual confounding in pharmacoepidemiologic studies that use health care utilization databases. Methods Four basic approaches to sensitivity analysis were identified: (1) sensitivity analyses based on an array of informed assumptions; (2) analyses to identify the strength of residual confounding that would be necessary to explain an observed drug-outcome association; (3) external adjustment of a drug-outcome association given additional information on single binary confounders from survey data using algebraic solutions; (4) external adjustment considering the joint distribution of multiple confounders of any distribution from external sources of information using propensity score calibration. Conclusion Sensitivity analyses and external adjustments can improve our understanding of the effects of drugs and biologics in epidemiologic database studies. With the availability of easy-to-apply techniques, sensitivity analyses should be used more frequently, substituting qualitative discussions of residual confounding. Copyright (c) 2006 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available